YL201

Overview

YL201 is an investigational antibody-drug conjugate (ADC) targeting CD276 (B7-H3), an overexpressed checkpoint ligand in nasopharyngeal carcinoma (NPC) and other solid tumors.

Evidence in the corpus

• YL201 anti-B7-H3 ADC in advanced solid tumors including NPC (NCT05434234/NCT06057922, NPC sub-cohort n=70): ORR 48.6%; median PFS 7.8 months; grade ≥3 TRAE 54.5% PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.